Zhang Y, Yu W Z, Yin Z D, Wang T Z, Sun X D, Xu A Q
Tianjin Center for Disease Control and Prevention, Tianjin 300011, China.
National Immunization Programme, China Center for Disease Control and Prevention, Beijing 100050, China.
Zhonghua Yu Fang Yi Xue Za Zhi. 2023 Jul 6;57(7):1082-1095. doi: 10.3760/cma.j.cn112150-20230419-00309.
During the global efforts to prevent and control the COVID-19 pandemic, extensive research and development of SARS-CoV-2 vaccines using various technical approaches have taken place. Among these, vaccines based on adenovirus vector have gained substantial knowledge and experience in effectively combating potential emerging infectious diseases, while also providing novel ideas and methodologies for vaccine research and development (R&D). This comprehensive review focuses on the adenovirus vector technology platform in vaccine R&D, emphasizing the importance of mucosal immunity induced by adenoviral vector-based vaccine for COVID-19 prevention. Furthermore, it analyzes the key technical challenges and obstacles encountered in the development of vaccines based on the adenovirus vector technology platform, with the aim of providing valuable insights and references for researchers and professionals in related fields.
在全球防控新冠疫情的努力中，人们运用各种技术手段对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗进行了广泛研发。其中，基于腺病毒载体的疫苗在有效对抗潜在新发传染病方面积累了丰富的知识和经验，同时也为疫苗研发提供了新的思路和方法。这篇综述聚焦于疫苗研发中的腺病毒载体技术平台，强调基于腺病毒载体的新冠疫苗诱导的黏膜免疫对预防新冠的重要性。此外，还分析了基于腺病毒载体技术平台开发疫苗时遇到的关键技术挑战和障碍，旨在为相关领域的研究人员和专业人士提供有价值的见解和参考。
Zotero 插件